Your browser doesn't support javascript.
Accumulation of CD28null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients.
Coleman, Mia J; Zimmerly, Kourtney M; Yang, Xuexian O.
  • Coleman MJ; Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
  • Zimmerly KM; Class of 2023, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
  • Yang XO; Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
Biomolecules ; 11(10)2021 09 29.
Article in English | MEDLINE | ID: covidwho-1512106
ABSTRACT
Coronavirus disease 2019 (COVID-19), a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes infectious disease, and manifests in a wide range of symptoms from asymptomatic to severe illness and even death. Severity of infection is related to many risk factors, including aging and an array of underlying conditions, such as diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and cancer. It remains poorly understood how these conditions influence the severity of COVID-19. Expansion of the CD28null senescent T-cell populations, a common phenomenon in aging and several chronic inflammatory conditions, is associated with higher morbidity and mortality rates in COVID-19. Here, we summarize the potential mechanisms whereby CD28null cells drive adverse outcomes in disease and predispose patients to devastating COVID-19, and discuss possible treatments for individuals with high counts of CD28null senescent T-cells.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / CD28 Antigens / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Biom11101425

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / CD28 Antigens / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Biom11101425